Neoadjuvant Bevacizumab in Newly Diagnosed, Surgically Resectable Glioblastoma: A Systematic Review and Meta-Analysis of Survival and Functional Outcomes

⚕️

This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The Big Picture: The "Tumor Garden" Problem

Imagine a patient's brain is a garden, and Glioblastoma (GBM) is a very aggressive, fast-growing weed that has taken over. The standard way to handle this weed is to cut it out (surgery) and then spray it with poison (chemotherapy and radiation) to kill the roots.

However, this weed is tricky. It often comes back, and the area around it is usually a swampy mess of fluid (edema) that makes the brain swollen and the patient feel terrible.

The Question: What if we sprayed a special "anti-swamp" medicine (Bevacizumab) before we even try to cut the weed out? Would this dry up the swamp, make the surgery easier, and help the patient live longer?

This paper is a Systematic Review and Meta-Analysis. Think of this as a "Super-Report" where the authors gathered every single study they could find on this specific idea, combined the data, and asked: "Does this actually work?"

The Investigation: Gathering the Clues

The authors acted like detectives. They searched through thousands of medical studies (like looking through a massive library) and found 10 studies that fit their criteria.

The Players: These studies involved 751 patients with newly diagnosed brain tumors who were scheduled for surgery.
The Experiment: Some patients got the standard treatment (Surgery + Chemo). Others got the "Super-Medicine" (Bevacizumab) before the surgery, sometimes mixed with chemo, and then had the surgery.
The Goal: They wanted to see two things:
1. Survival: Did the patients live longer?
2. Function: Did the patients feel better, think clearer, and need fewer steroids (strong anti-swamp drugs that have bad side effects)?

The Findings: The Good, The Bad, and The Ugly

Here is what the "Super-Report" discovered, broken down simply:

1. The Survival Score (The "Longevity" Test)

The Result: No significant difference.
The Analogy: Imagine two groups of runners. One group gets a special energy drink before the race; the other doesn't. The study found that the runners with the special drink didn't finish the race any faster or live longer than the others.

The Data: The math showed that giving the medicine before surgery did not significantly extend the total time patients lived. The "Hazard Ratio" was close to 1, meaning the odds of survival were roughly the same for both groups.

2. The Functional Score (The "Quality of Life" Test)

The Result: Yes, there was a benefit here.
The Analogy: Even though the runners didn't finish the race faster, the group with the special drink felt much less exhausted during the race. They could walk straighter, think more clearly, and didn't need as many painkillers.

The Data: Patients who got the medicine before surgery had:
- Less Swelling: The "swamp" around the tumor dried up significantly (up to 54% less fluid).
- Better Performance: Their "Karnofsky Performance Status" (a score for how well you can do daily tasks) went up.
- Fewer Steroids: They needed fewer strong steroid drugs, which usually cause weight gain, mood swings, and bone weakness.
- Easier Surgery: Because the swelling went down, the surgeons could see the edges of the tumor better, making the operation safer and more precise.

3. The Safety Check (The "Side Effects" Test)

The Result: It's mostly safe, but watch out for the "healing" issue.
The Analogy: The medicine is like a strong glue that stops leaks. But if you use it right before you try to stitch a wound, the glue might stop the skin from knitting back together properly.

The Data: There were no major bleeding issues during surgery. However, there was a slightly higher risk of wound healing problems (the incision taking longer to close) and high blood pressure.

4. The "Pseudo-Response" Trap

The Warning: The paper mentions a tricky phenomenon called "Pseudo-response."
The Analogy: Imagine a balloon filled with water. If you poke a hole in it, the water leaks out, and the balloon looks smaller. But the rubber (the tumor cells) is still there, just deflated.

The Reality: Bevacizumab dries up the fluid so fast that the tumor looks like it's shrinking on an MRI scan. But sometimes, the actual cancer cells are still hiding there, just waiting to grow back. This makes it hard to tell if the treatment is truly killing the cancer or just hiding it temporarily.

The Verdict: What Should We Do?

The authors conclude with a balanced view:

Don't expect a miracle cure: Using this medicine before surgery does not currently prove that patients will live longer.
Do expect a helper: It is excellent at making the patient feel better right now. It reduces swelling, improves brain function, and makes the surgery safer to perform.
The Cost: The medicine is very expensive. Since it doesn't extend life, the "cost-effectiveness" is low. It's like buying a very expensive umbrella that keeps you dry for an hour but doesn't stop the rain forever.

The Bottom Line

Think of Neoadjuvant Bevacizumab not as a cure, but as a tactical tool.

If you are a surgeon trying to remove a tumor from a swollen, messy brain, this drug is like a high-powered vacuum that sucks up the water and clears the fog. It makes the job easier and the patient feel better in the short term. But, unfortunately, it doesn't seem to stop the weed from growing back any faster or slower than the standard treatment.

Future Needs: The authors say we need bigger, better studies to figure out exactly who benefits most. Maybe it works great for specific types of tumors or specific patients, but we need to find the "key" to unlock that potential. For now, it's a helpful assistant, not a game-changer for survival.

1. Problem Statement

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a median overall survival (OS) of only 14–16 months despite the standard of care (maximal safe resection followed by chemoradiotherapy with temozolomide, the Stupp protocol).

Clinical Challenge: Patients often suffer from severe peritumoral edema, neurological deterioration, and steroid dependence, which compromise functional independence and quality of life.
Intervention: Bevacizumab (BEV), an anti-VEGF monoclonal antibody, is FDA-approved for recurrent GBM due to its ability to reduce edema and improve progression-free survival (PFS), though it has not shown a definitive OS benefit in adjuvant settings.
Knowledge Gap: While theoretically, administering BEV neoadjuvantly (before surgery) could reduce edema, improve surgical resection margins, and stabilize neurological function, evidence regarding its impact on survival and functional outcomes in newly diagnosed, resectable GBM is sparse, heterogeneous, and lacks a comprehensive synthesis.

2. Methodology

The study followed the PRISMA 2020 guidelines and was registered with PROSPERO (CRD420251078761).

Search Strategy: A comprehensive search was conducted across PubMed, Embase, Scopus, Web of Science, and Cochrane Library up to July 20, 2025. No language restrictions were applied.
Eligibility Criteria (PICOS):
- Population: Adults (≥18) with newly diagnosed, histologically confirmed, surgically resectable GBM.
- Intervention: Neoadjuvant Bevacizumab (administered pre-operatively), either as monotherapy or in combination with temozolomide (TMZ) and/or radiotherapy.
- Comparator: Standard of care (Surgery + RT/TMZ) or placebo without preoperative BEV.
- Outcomes: Primary: Overall Survival (OS) and Progression-Free Survival (PFS). Secondary: Functional status (Karnofsky Performance Status - KPS), steroid use, radiological response, and biomarkers.
- Study Design: RCTs, non-randomized clinical trials, and cohort studies.
Data Synthesis:
- A random-effects model was used to pool Hazard Ratios (HR) for OS and PFS.
- Heterogeneity was assessed using Cochran's Q and $I^2$ statistics.
- Certainty of evidence was evaluated using the GRADE framework.
Selection Process: From 9,358 initial records, 10 studies met inclusion criteria for qualitative synthesis, with 4 studies (n=751 participants) providing sufficient data for quantitative meta-analysis.

3. Key Contributions

First Comprehensive Synthesis: This is the first meta-analysis exclusively focusing on the neoadjuvant (pre-operative) use of BEV in newly diagnosed GBM, integrating survival, functional, radiological, and molecular data.
Differentiation of Effects: The study distinguishes between the biological effects of BEV (edema reduction, vascular normalization) and its clinical impact on long-term survival, addressing the "PFS-OS divergence" often seen in anti-angiogenic therapies.
Functional & Surgical Insights: It highlights the potential of neoadjuvant BEV to improve surgical conditions (tumor-brain interface clarity) and functional status (KPS, steroid sparing), even if survival benefits are unproven.
Biomarker Correlation: The review synthesizes emerging data on histopathological changes (e.g., reduced microvessel density, hypoxia modulation) and their transient nature.

4. Key Results

A. Survival Outcomes (Quantitative Meta-Analysis)

Overall Survival (OS): Pooled HR = 0.72 (95% CI: 0.42–1.25, p=0.246). No statistically significant improvement in OS.
Progression-Free Survival (PFS): Pooled HR = 0.72 (95% CI: 0.42–1.22, p=0.220). No statistically significant improvement in PFS.
Heterogeneity: Statistical heterogeneity was low ( $I^2 = 0\%$ ), but clinical heterogeneity was high due to varying protocols (dosing, timing to surgery, concomitant therapies).
Certainty: The certainty of evidence for survival endpoints was rated as Low (GRADE).

B. Functional and Neurological Outcomes

KPS Improvement: Qualitative data from three studies suggested trends toward improved KPS. For example, Tanaka et al. (2024) reported KPS increasing from 83.3 to 94.7.
Steroid Dependence: BEV was associated with reduced corticosteroid requirements. In Chinot et al. (2016), 70.6% of BEV patients discontinued steroids vs. 47.5% in the control group.
Cognitive Function: Improvements in Mini-Mental State Examination (MMSE) scores were observed in some cohorts.

C. Radiological and Molecular Findings

Edema and Tumor Volume: Consistent reductions in peritumoral edema (FLAIR volume reduction ~54%) and contrast-enhancing tumor volume (T1CE reduction ~36–38%) were observed.
Pseudoresponse: The rapid radiological response is attributed to vascular normalization and reduced permeability rather than true tumor cytoreduction.
Histopathology: Preoperative BEV led to transient vascular normalization (reduced CD34, ERG), decreased hypoxia markers (CA9, HIF-1α), and reduced stemness markers (Nestin). However, recurrence specimens showed adaptive resistance (re-emergence of hypoxia and VEGF upregulation).

D. Safety Profile

Perioperative Risks: No intraoperative hemorrhages were reported in the available quantitative data.
Adverse Events: Common issues included hypertension, thromboembolism, and delayed wound healing. One study (Chinot 2016) reported higher rates of Grade 3–5 adverse events in the BEV arm (72.6% vs. 63.0%).
Wound Healing: While generally safe, there is a theoretical risk of delayed wound healing, necessitating appropriate washout intervals (typically 3–5 weeks) before surgery.

5. Significance and Conclusion

Clinical Implications:

Not a Disease-Modifying Agent: Neoadjuvant BEV does not currently demonstrate a statistically significant survival benefit for newly diagnosed GBM. It should not replace standard of care or be adopted routinely outside of clinical trials.
Perioperative Adjunct: The intervention shows promise as a perioperative adjunct to:
- Reduce peritumoral edema and mass effect.
- Improve functional status (KPS) and reduce steroid dependence.
- Potentially facilitate safer, more extensive resections, particularly in eloquent brain regions.
Cost-Effectiveness: Current economic analyses suggest the intervention is not cost-effective due to high drug costs and the lack of OS benefit.

Limitations:

Small sample sizes and a scarcity of RCTs (only 2 of 10 studies were RCTs).
High clinical heterogeneity in treatment protocols (timing, dosing, maintenance).
Inconsistent reporting of safety and functional outcomes.
Low certainty of evidence (GRADE).

Future Directions:
The authors call for large, multicenter, well-designed RCTs with standardized neoadjuvant protocols. Future research should focus on:

Biomarker-driven patient selection (e.g., necrotic volume, hypoxic burden).
Integration of translational endpoints (imaging + molecular markers).
Systematic assessment of quality of life, seizure control, and long-term surgical outcomes.

Final Verdict: Neoadjuvant Bevacizumab offers symptomatic and functional benefits and may improve surgical conditions, but it fails to improve overall survival in the current evidence base. Its role remains investigational.